Q-omics provides the consensus-scored SAMD5 profile across patient tissues and cancer cell-line models. SAMD5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SAMD5 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SAMD5 RNA expression shows 17,707 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where SAMD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAMD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAMD5 survival associations across molecular data types. SAMD5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAMD5 RNA expression–survival associations across cancer types. High SAMD5 expression shows unfavorable associations in MESO, KIRP, UCEC and ACC, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SAMD5 RNA expression.
This table summarizes SAMD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SAMD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAMD5 shows lower tumor expression in HNSC, LUAD, THCA, UCEC, LIHC and LUSC. The HNSC box plot shows higher SAMD5 RNA expression in normal versus tumor tissue (log2 FC = −1.715, t-test p < 0.001).
This table shows molecular features associated with SAMD5 in patient tissues and cancer cell lines. In patient samples, SAMD5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SAMD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
